secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0000950170-23-027497
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya amends severance plan: CEO gets 12-18 months salary; shareholders approve officer exculpation
--------------------------------------------------------------------------------

- CEO Faraz Ali: non-CIC severance 12 months base; CIC severance 18 months base + 150% target bonus; COBRA up to 18 months.
- Other named execs: non-CIC 9 months base; CIC 12 months base + 100% bonus; COBRA up to 12 months; equity accelerated.
- Stockholders approved amendment to certificate of incorporation to limit officer personal liability for monetary damages.
- Annual meeting: Directors Burroughs, Chen, Stehman-Breen elected; Deloitte & Touche ratified as independent auditor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/0000950170-23-027497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023027497/tnya-20230608.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer